3648_EchoIQ-ES_Logo_FA_RGB_REV

Echo IQ exhibits at MedAxiom Transforum ’23!

Echo IQ is exhibiting at the MedAxiom Transforum Spring Meeting in Orlando, Florida from April 20 – 22.

Echo IQ has developed an AI clinical decision-support tool that analyses echo measurement data to show risk indicators for structural heart disease.

EchoSolv™ AS has been clinically validated to identify up to 72% more high risk patients than found by cardiologists alone, including 100% identification of in-guideline severe Aortic Stenosis patients.

We’ve accomplished this by leveraging the largest global database of echocardiograms tied to mortality, NEDA.

Our clinical validation

St Vincent’s Hospital, Melbourne: EchoSolv™ AS study of 8,257.

By Imelda Cotton - December 15, 2022


Read More

Enhanced Diagnosis of Severe Aortic Stenosis Using Artificial Intelligence: A Proof-of-Concept Study of 530,871 Echocardiograms.

By David Playford MBBS, PhD, Edward Bordin BSc, ME, Razali Mohamad BCM, ME, Simon Stewart PhD, Geoff Strange BN, PhD.


Read More

The Alarm Blares for Undertreatment of Aortic Stenosis.

Lindman B, Lowenstern A, et al. J Am Coll Cardiol. 2022 Mar, 79 (9) 878–881.


Read More

Our Hidden Ageing: Time To Listen To The Heart

Baker Institute


Read More

Hear what Dr David Playford has to say about EchoSolv™ AS.

Dr. Playford, MBBS PhD FRACP (gen med) FRACP (cardiol) FCSANZ FACC FESC; Professor and Head of Cardiology, University of Notre Dame; consultant clinical and imaging cardiologist Advara HeartCare; Founder and Co-Chief Investigator National Echo Database Australia; Chief Medical Advisor Echo IQ.

Book a meeting with us!

This field is for validation purposes and should be left unchanged.

Echo IQ has developed an AI diagnostic tool that will revolutionise the diagnosis of structural heart disease. Specifically, it is designed to reduce the incidence of undetected and misdiagnosed cardiac issues.

Echo IQ Limited 

white_logo
Echo IQ has developed an AI diagnostic tool that will revolutionise the diagnosis of structural heart disease. Specifically, it is designed to reduce the incidence of undetected and misdiagnosed cardiac issues.

Echo IQ Limited 

#aiwithheart

EchoSolv™ is currently available in the US and Australia as a guideline-led decision-support tool. Full
phenotyping capabilities will be available pending FDA approval.

All rights reserved. Copyright © 2023 Echo IQ.
Designed and Developed by Brand for Brands.